Uptravi was approved in 2016 to treat Pulmonary Arterial Hypertension, PAH. We now have more than four years of experience with this medication. There are three broad pathways that PAH medications impact. 3 Pathways PAH Medications Impact The endothelin pathway is overactive in PAH and leads to excessive blood vessel squeezing and … [Read more...]
Exciting New Clinical Trials in PAH
The wheels of progress continue to move forward in PAH research. Two companies in particular are preparing to launch very exciting clinical trials. Gossamer Bio Inhaled Drug Study Gossamer Bio, a biopharmaceutic company is preparing to launch a new phase 2 clinical research trial using an inhaled tyrosine kinase inhibitor. About 10 years … [Read more...]
Pulmonary Hypertension and COVID-19
We are in the midst of the greatest health crisis since HIV (human immunodeficiency virus). The last time the world saw a respiratory illness of this severity was in 1918 when a very aggressive strain of influenza swept across the world. Today we are squarely in the middle of the COVID-19 pandemic. Millions of Americans will be infected and many … [Read more...]
Tyrosine Kinase Inhibition and Pulmonary Arterial Hypertension
30 years ago PAH scientists and doctors believed that PAH was caused by inappropriate or excessive squeezing (vasoconstriction) of the pulmonary arteries. The earliest medications to treat PAH focused on relaxing the pulmonary arteries. Over the next decade we learned that PAH is a much more complex disorder than just blood vessels squeezing too … [Read more...]
Liquidia Files for Approval of Inhaled Treprostinil
We were excited to hear that Liquidia has filed with the FDA for approval of their drug inhaled treprostinil. They had already reported exciting results with their medication, showing that it was well tolerated and maintained or improved six minute walk distance. Currently, United Therapeutics makes Tyvaso, which is treprostinil for inhalation. Tyvaso … [Read more...]
